Conference News In Brief: Attorneys Watching FDA’s ING Guidance; PCPC Priorities; More
This article was originally published in The Rose Sheet
Legal experts at an ACI regulatory forum on cosmetics stressed the importance of submitting comments on recently released FDA guidance that could potentially obligate firms studying cosmetic ingredients to file Investigation New Drug Applications. Meanwhile, PCPC Board Chairman Scott Beattie provided an overview of key initiatives for the year at the trade group’s annual meeting in Palm Beach, Fla.
You may also be interested in...
Proposition 65 lawsuits have increased for the cosmetics industry with the expiration of a grace period for new ingredients added to California’s list of substances linked to cancer or reproductive toxicity. Attorneys from Edwards Wildman offer perspective on the issue and its impact on industry.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.